New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
07:53 EDTMRX, VRXValeant receives FTC clearance for Medicis acquisition
Valeant Pharmaceuticals (VRX) announced that the U.S. Federal Trade Commission, or FTC, has completed its review of the proposed acquisition of Medicis Pharmaceutical Corporation (MRX) by Valeant and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 without conditions. The grant of early termination is effective as of November 15. The company expects to close the merger within four business days following satisfaction of all closing conditions.
News For VRX;MRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
08:02 EDTVRXValeant announces FDA approval of Onexton gel
Subscribe for More Information
November 21, 2014
10:26 EDTVRXOptions with decreasing implied volatility
Subscribe for More Information
November 20, 2014
18:00 EDTVRXPS Fund 1 sells 2.24M Allergan shares allocated to Valeant USA
Subscribe for More Information
11:41 EDTVRXValeant announces new $2B securities repurchase program
Subscribe for More Information
10:35 EDTVRXOptions with decreasing implied volatility
Options with decreasing implied volatility: DKS SPLS WB GMCR VRX HTZ WSM VIPS BBY AMAT
08:36 EDTVRXZoetis guidance positive, says BMO Capital
Subscribe for More Information
November 19, 2014
17:03 EDTVRXValeant request withdrawal of registration, proxy statements
The company’s request is based on its termination of the exchange offer to which the Registration Statement, File No. 333-196856, relates on November 19, 2014. Valeant also requests the immediate withdrawal of the Preliminary Proxy Statement on Schedule 14A, File No. 001-14956, filed with the Commission on June 24, as amended on July 22, August 22, and September 22. In light of the fact that Valeant is withdrawing the Registration Statement, it no longer believes it is desirable to pursue the matters referred to in the Proxy Statement.
07:52 EDTVRXInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
13:34 EDTVRXActavis rallies after analysts push targets north of $300
Shares of drug maker Actavis (ACT) are climbing after a number of analysts cheered the company's acquisition of Allergan (AGN), and activist investor Bill Ackman said he supported the transaction, according to CNBC. WHAT'S NEW: Piper Jaffray analyst David Amsellem responded to Actavis' acquisition of Allergan by hiking his price target on the name to $338 from $280. The combined company has durable assets, a cost-efficient infrastructure, and the willingness to maintain a strong R&D infrastructure, contended Amsellem. Actavis' price-to-earnings ratio is likely to increase, since it has durable assets, while it his very likely to sustain growth of at least 10%, the analyst added. He kept an Overweight rating on the shares. Also extremely upbeat on Actavis following the deal was UBS analyst Marc Goodman. Actavis provides "the best value in the sector" following the deal, as the transaction should accelerate the company's revenue and profit growth, Goodman believes. That growth, in turn, should propel Actavis' price-to-earnings multiple higher, the analyst predicted. He hiked his price target on Actavis to $333 from $278 and kept a Buy rating on the stock. Meanwhile, Pershing Square's Bill Ackman said that he supported Actavis' takeover of Allergan, CNBC reported this morning. The owner of a large stake in Allergan, Ackman had been trying to get the drug maker to sell itself to Valeant (VRX). The activist investor said today that he would no longer push Allergan to hold a special meeting on December 18, CNBC noted. PRICE ACTION: In mid-afternoon trading, Actavis surged 7.5% to $266.50, while Allergan gained 2% to $214.
08:02 EDTVRXValeant announces FDA, Health Canada approval to market Ideal Implant
Valeant Pharmaceuticals and Ideal Implant Incorporated announced the receipt of approval from the U.S. Food and Drug Administration and Health Canada to market the IDEAL IMPLANT Saline-filled Breast Implant for use in primary breast augmentation or replacement of existing augmentation implants. The FDA approval of the IDEAL IMPLANT was based on an extensive review of various studies and data including a U.S. clinical trial that began in 2009 with 45 plastic surgeons and 502 women, who underwent breast augmentation or replacement of augmentation implants. The clinical trial is on-going and will continue to provide follow-up data through 2020.
07:48 EDTVRXValeant not likely to raise bid for Allergan, says Canaccord
Subscribe for More Information
06:49 EDTVRXValeant likely to pursue more moderate-sized deals, says Piper Jaffray
Subscribe for More Information
November 17, 2014
09:32 EDTVRXValeant says cannot justify paying $219 per share for Allergan
Valeant Pharmaceuticals (VRX) commented on the announcement that Allergan (AGN) and Actavis (ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock: "We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan. Our business is performing extremely well as evidenced by our third quarter results, our expected strong fourth quarter, and our robust outlook for 2015, and I am confident in our continued ability to generate exceptional shareholder value. We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders."
06:05 EDTVRXActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
14:02 EDTVRXAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use